NascaCell Technologies AG
NascaCell Technologies AG is a global leader in the automated production and marketing of aptamers and the generation of Microbodies™.
Aptamers are small, functional oligonucleotides binding to target proteins with very high affinities and specificities. Because of their drug like binding characteristics, aptamers typically show strong inhibition of protein function. NascaCell selects aptamers in a rapid, automated procedure. This allows their generation in 8-10 weeks with a proven track record in target validation and drug discovery.
Microbodies™ are very small (approx. 35 amino acids) and extremely stable proteins. Active peptides can be grafted into the Microbodies™ or new sequences identified with bacterial display. Microbodies™ combine the selectivity of biologic agents with the ease of handling and storage of small molecule drug compounds and can be used both as pharmaceutical active compounds and as diagnostic and preparative tools.
NascaCell Technologies AG is a global leader in the automated production and marketing of aptamers and the generation of Microbodies™.
Aptamers are small, functional oligonucleotides binding to target proteins with very high affinities and specificities. Because of their drug like binding characteristics, aptamers typically show strong inhibition of protein function. NascaCell selects aptamers in a rapid, automated procedure. This allows their generation in 8-10 weeks with a proven track record in target validation and drug discovery.
Microbodies™ are very small (approx. 35 amino acids) and extremely stable proteins. Active peptides can be grafted into the Microbodies™ or new sequences identified with bacterial display. Microbodies™ combine the selectivity of biologic agents with the ease of handling and storage of small molecule drug compounds and can be used both as pharmaceutical active compounds and as diagnostic and preparative tools.